ARTICLE | Financial News

Clearside, G1 price upsized follow-ons

March 16, 2018 5:03 PM UTC

Ophthalmology company Clearside Biomedical Inc. (NASDAQ:CLSD) and cancer company G1 Therapeutics Inc. (NASDAQ:GTHX) each priced bumped-up follow-ons on the back of positive data, raising a total of $199.8 million.

Clearside raised $85 million on March 8 through the sale of 6.5 million shares at $13 in a follow-on underwritten by J.P. Morgan, Cowen, Stifel, Needham and Wedbush. The price is a small premium over Clearside's closing price of $12.95 on March 6, when the company proposed after market hours to raise $75 million...